First Tracks Biotherapeutics Stock Price, News & Analysis
Company Description
First Tracks Biotherapeutics (NASDAQ: TRAX) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $660.2M, ranking #3,263 among all listed U.S. companies by market cap.
TRAX stock has declined 2.4% over the past year. Shares last traded at $18.16.
This page provides a comprehensive overview of TRAX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
First Tracks Biotherapeutics (TRAX) stock last traded at $18.16, down 7.45% from the previous close. Over the past 12 months, the stock has lost 2.4%. At a market capitalization of $660.2M, TRAX is classified as a small-cap stock with approximately 34.7M shares outstanding.
TRAX Rankings
Latest News
First Tracks Biotherapeutics has 1 recent news article, with the latest published 5 days ago. View all TRAX news →
SEC Filings
Insider Radar
Insider selling at First Tracks Biotherapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
TRAX Company Profile & Sector Positioning
First Tracks Biotherapeutics (TRAX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.